
Highlights from AUA2025: Advances in NMIBC (2025)

Highlights from AUA2025: Advances in NMIBC will discuss the best in the latest advancements in Non-Muscle Invasive Bladder Cancer (NMIBC) from the AUA Annual Meeting!
This activity is designed to increase the urologist’s understanding of how to translate the latest clinical guidelines and scientific advances into their routine clinical practice, improving the care of patients with NMIBC. In this interactive discussion, a multidisciplinary panel of experts highlight the latest in treatment of non-muscle invasive bladder cancer (NMIBC) presented throughout the AUA2025, such as plenary sessions and courses.
This educational activity is supported by independent educational grants from:
- Merck & Co., Inc.
- ImmunityBio, Inc.
Target Audience
- Urologists
- Urologists in training
- Non-physician providers involved in urology
Learning Objectives
At the conclusion of this CME activity, participants will be able to:
- Recognize recent developments in the management of NMIBC.
- Evaluate new and emerging therapies for NMIBC, such as novel intravesical agents and immunotherapies, their mechanism of action and related adverse events.
- Employ current management approaches for NMIBC.
- Utilize risk stratification to guide treatment decisions for NMIBC patients.
- Implement diagnostic techniques for NMIBC, including cystoscopy, urine cytology, biomarkers, and advanced imaging modalities.
Education Council Disclosures
Education Council Disclosures.pdf
COI Work Group Disclosures
COI Review Workgroup Disclosures.pdf
Faculty Disclosures
| Name | Company Name | Relationship Type | End Date |
|---|---|---|---|
| Bree, Kelly | Nothing relevant to disclose | ||
| Arruda, John B. | Nothing relevant to disclose | ||
| Packiam, Vignesh | Veracyte | Consultant or Advisor | Current |
| Packiam, Vignesh | Urogen | Consultant or Advisor | 04/01/2025 |
| Packiam, Vignesh | Ferring | Consultant or Advisor | 04/01/2025 |
| Packiam, Vignesh | Photocure | Consultant or Advisor | Current |
| Porten, Sima Prabodh | Photocure | Scientific Study or Trial | Current |
| Porten, Sima Prabodh | Stryker | Consultant or Advisor | Current |
| Porten, Sima Prabodh | AstraZeneca | Consultant or Advisor | Current |
| Porten, Sima Prabodh | Pacific Edge | Consultant or Advisor | Current |
| Porten, Sima Prabodh | Vesica Health | Consultant or Advisor | Current |
| Grivas, Petros | Abbvie | Consultant or Advisor | 01/24/2024 |
| Grivas, Petros | Acrivon Therapeutics | Scientific Study or Trial | Current |
| Grivas, Petros | ALX Oncology | Scientific Study or Trial | Current |
| Grivas, Petros | Astellas Pharma | Consultant or Advisor | Current |
| Grivas, Petros | AstraZeneca | Consultant or Advisor | 01/25/2024 |
| Grivas, Petros | Bicycle Therapeutics | Consultant or Advisor | 05/31/2024 |
| Grivas, Petros | Bristol-Myers Squibb | Consultant or Advisor | 01/26/2024 |
| Grivas, Petros | Daiichi Sankyo, Inc. | Consultant or Advisor | 09/04/2024 |
| Grivas, Petros | EMD Serono | Consultant or Advisor | Current |
| Grivas, Petros | Foundation Medicine | Consultant or Advisor | 02/12/2025 |
| Grivas, Petros | Fresenius Kabi | Consultant or Advisor | 06/01/2023 |
| Grivas, Petros | Genentech | Scientific Study or Trial | Current |
| Grivas, Petros | Gilead | Consultant or Advisor | 01/24/2024 |
| Grivas, Petros | Merck & Co | Consultant or Advisor | 02/28/2024 |
| Grivas, Petros | Pfizer | Consultant or Advisor | Current |
| Grivas, Petros | Replimune | Consultant or Advisor | 07/19/2024 |
| Grivas, Petros | Roche | Consultant or Advisor | 01/27/2024 |
| Grivas, Petros | SeaGen | Consultant or Advisor | 10/23/2023 |
| Grivas, Petros | Strata Oncology | Consultant or Advisor | Current |
All relevant financial relationships have been mitigated.
AUA Office of Education Staff have nothing to disclose.
Method of Participation: Learners will participate in this online educational activity by viewing the webcast and completing the post-test and evaluation. To claim CME credit for this enduring material, learners must complete the post-test, passing with 80% accuracy, and submit the program evaluation.
Release Date: May, 2025
Expiration Date: May, 2026
Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation: The American Urological Association designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA Disclosure Policy: All persons in a position to control the content of a CME activity are required to disclose to the AUA, as the ACCME-accredited provider, all financial relationships with any ineligible company (formerly commercial interests) during the previous 24 months. An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The AUA must determine if the individual’s relationships are relevant to the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners with information so they can make their own judgments.
Mitigation of Identified Conflict of Interest: All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of relevant financial relationships that result in conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation.
Off-label or Unapproved Use of Drugs or Devices: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Non-Physician Participation

Facebook
X
LinkedIn
Forward